RxDoctor Payments Data

Jacob Forsythe

Acute Care · Maple Grove, MNNPI 1487332375

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,458 of the $6,519 with a category attached, or 68.4%. 15 manufacturers reported payments, led by Boston Scientific at 24.7% of the total. Reporting peaked in 2024 at $3,876 and has fallen 61.8% since, to $1,479 in 2025. Among acute care clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,519in general payments, 2019–2025

Across 80 payments — averaging $81.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Si-bone, Inc.$2K
  • Medtronic$590
  • Saluda Medical Americas, Inc.$572
  • Curonix LLC$517
  • SPR Therapeutics, Inc$482
  • plus $1K from 9 others

What the payments were for

  • Travel & lodging$2,06132%
  • Food & beverage$4,45868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,519 in reported general payments places this provider in the 95th percentile of 51 acute care providers in Minnesota.

See all acute care providers in Minnesota

Medicare billing

Part B allowed, 2024
$73,036
Medicare patients
228
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl71$42,329
OxycontinOxycodone Hcl35$16,325
Buprenorphine46$10,687
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl61$9,067
SuboxoneBuprenorphine Hcl/Naloxone Hcl24$8,217
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen311$6,316
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen257$5,480
Gabapentin302$3,880
Pregabalin204$3,682
Tizanidine Hcl183$2,414
Oxycodone Hcl186$2,338
Lidocaine27$1,562
Methocarbamol81$1,336
Tramadol Hcl ErTramadol Hcl12$963
Tramadol Hcl164$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$32$42,32971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 acute care providers in Minnesota.

Other acute care in Maple Grove

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →